Opinion|Videos|December 23, 2024
Evaluating Cognitive Health: Tools, Markers, and the Concept of Cognitive PIRA
Author(s)Gabriel Pardo, MD, FAAN, Martin Belkin, DO
Key Takeaways
- Advanced imaging, CSF analysis, and peripheral blood markers are crucial for assessing cognitive health, offering insights into brain structure and function.
- Cognitive PIRA underscores the need to monitor cognitive changes that occur without clinical relapses, necessitating comprehensive assessment strategies.
Panelists discuss how clinicians can evaluate cognitive health using neuroimaging, cerebrospinal fluid (CSF)/blood biomarkers, and comprehensive assessments. Understanding concepts like cognitive progressive irreversible reductions in activity (PIRA) and focusing on multifaceted interventions—including lifestyle modifications, early detection, and personalized strategies—can help maintain cognitive wellness and mitigate decline.
Advertisement
Video content above is prompted by the following:
- Which tools, imaging, CSF, or peripheral blood markers can clinicians use to evaluate cognitive health in a patient? Please explain.
- What are your thoughts about the concept of cognitive PIRA?
- What advice would you have for health care providers so they can help patients better maintain their cognitive health?
Advertisement
Related to this article
Jeffrey Cohen, MD, professor of neurology and staff physician at the Cleveland Clinic Mellen Center for Multiple Sclerosis, discusses interim BREAKFREE-2 findings for zola-cel, a CD19-directed CAR T cell therapy, in relapsing and progressive MS.
Kim Henriksen, PhD, discusses research evaluating blood-based biomarkers of blood-brain barrier remodeling and immune cell activity in multiple sclerosis, including their potential to track treatment responses and inform future biomarker development.
Terrie Livingston, PharmD, vice president of medical affairs at Octave Bioscience, discussed the evolving role of blood-based biomarkers in multiple sclerosis care.
New biomarker data showed smaller post-onset increases in plasma neurofilament light chain and glial fibrillary acidic protein with privosegtor added to steroids in patients with acute optic neuritis.
Two-year data from the phase 2 DAZALS trial showed a lower risk of death with dazucorilant 300 mg/day vs placebo in ALS, although the study did not meet its functional primary end point.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 6, 2026.
Williams, MD, is joined by Marcus Gates, MD, and they discuss recognizing cervical nerve root and spinal cord compression, navigating treatment options, and determining when surgery may be appropriate.
Servier reported that sevasemten did not meet its primary or secondary endpoints in the pivotal GRAND CANYON trial for Becker muscular dystrophy.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
QurAlis Reports ANQUR Interim Data for STATHMIN-2-Targeting Agent QRL-201 in ALS
2
FDA Grants Priority Review to Huntington Disease Gene Therapy BLA, Sevasemten Misses Primary, Secondary End Points in BMD, Overviewing the 1-Year KYSA-8 Findings
3
PREVAiLS Phase 3 Trial Evaluates Pridopidine in Early, Rapidly Progressive ALS
4
ALS Agent Dazucorilant Associated With Lower 2-Year Mortality in Exploratory DAZALS Analysis
5